

CLAIMS

1. Group 2 allergen specific human IgE Fabs having the amino acid sequences as shown in SEQ ID No 2A-B or essentially homologous variants thereof.
2. Group 2 allergen specific human IgE Fabs encoded by the nucleic acid sequences as shown in SEQ ID No 1A-B or essentially homologous variants thereof.
3. Group 2 allergen specific human IgG comprising the variable regions of the IgE Fabs of claims 1 or 2
4. IgE-Fabs according to claims 1 or 2 or IgG according to claim 3, which are directed against Phl p 2.
5. IgE-Fabs according to any of the claims 1-2 or 4 and IgG according to claims 3 or 4, which are recombinantly produced.
6. A diagnostic reagent comprising the IgE-Fabs and/or IgG according to any of the claims 1-5, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.
7. A diagnostic kit comprising the reagent according to claim 6.
8. A vaccine against type I allergy, comprising the IgE-Fabs and/or IgG according to any of the claims 1-5, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.

9. Use of Phl p 2-specific IgE-Fabs and/or IgG according to any of the claims 1-5 or vaccine according to claim 8 for passive immunotherapy of type I allergy.

10. Use of Phl p 2-specific IgE-Fabs and/or IgG according to any one of the claims 1-5 or reagent according to claim 6 for diagnosing of type I allergy.

11. Use of Phl p 2-specific IgE-Fabs and/or IgG according to any one of the claims 1-5 for environmental allergen detection.

12. Use of Phl p 2-specific IgE-Fabs and/or IgG according to any one of the claims 1-5 for standardization of allergen extracts.